Abstract | INTRODUCTION: METHODS: We studied 432 patients with advanced NSCLC (stages IIIB-IV) treated with cisplatin and docetaxel and 89 healthy age-matched controls. Blood samples were collected before chemotherapy, and VEGF-A and sVEGFR-2 levels were determined by ELISA. RESULTS:
VEGF-A and sVEGFR-2 levels were higher in NSCLC patients than in the controls, but VEGF-A behaves as a better diagnostic biomarker. There were no significant associations between VEGF-A and sVEGFR-2 concentrations and clinical characteristics, such as ECOG-PS, gender, stage, histology, metastases, and treatment response. A patient subgroup characterized by a combination of high VEGF-A and low sVEGFR-2 levels exhibited the worst patient prognoses in terms of TTP and OS. CONCLUSIONS:
VEGF-A and sVEGFR-2 levels were significantly higher in patients than in the controls. A combination of VEGF-A and sVEGFR-2 can be used as an independent prognostic biomarker in advanced NSCLC.
|
Authors | Eloisa Jantus-Lewintre, Elena Sanmartín, Rafael Sirera, Ana Blasco, José Javier Sanchez, Miquel Tarón, Rafael Rosell, Carlos Camps |
Journal | Lung cancer (Amsterdam, Netherlands)
(Lung Cancer)
Vol. 74
Issue 2
Pg. 326-31
(Nov 2011)
ISSN: 1872-8332 [Electronic] Ireland |
PMID | 21481963
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Biomarkers, Tumor
- Taxoids
- Vascular Endothelial Growth Factor A
- Docetaxel
- Vascular Endothelial Growth Factor Receptor-2
- Cisplatin
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Biomarkers, Tumor
(blood)
- Carcinoma, Non-Small-Cell Lung
(diagnosis, drug therapy, pathology, physiopathology)
- Cisplatin
(administration & dosage)
- Disease Progression
- Docetaxel
- Female
- Humans
- Lung Neoplasms
(diagnosis, drug therapy, pathology, physiopathology)
- Male
- Middle Aged
- Neoplasm Staging
- Prognosis
- Taxoids
(administration & dosage)
- Vascular Endothelial Growth Factor A
(blood)
- Vascular Endothelial Growth Factor Receptor-2
(blood)
|